Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Kenvue Inc. (NYSE:KVUE). In a filing disclosed on September 04th, the Representative disclosed that they had sold between $1,001 and $15,000 in Kenvue stock on July 17th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Purchased $15,001 - $50,000 in shares of Mesabi Trust NYSE: MSB on 7/31/2026.
- Purchased $1,001 - $15,000 in shares of Praxis Precision Medicines NASDAQ: PRAX on 7/30/2026.
- Purchased $15,001 - $50,000 in shares of Alkermes NASDAQ: ALKS on 7/30/2026.
- Sold $15,001 - $50,000 in shares of Crinetics Pharmaceuticals NASDAQ: CRNX on 7/30/2026.
- Sold $100,001 - $250,000 in shares of Alibaba Group NYSE: BABA on 7/24/2026.
- Sold $1,001 - $15,000 in shares of Adobe NASDAQ: ADBE on 7/24/2026.
- Sold $1,001 - $15,000 in shares of Viavi Solutions NASDAQ: VIAV on 7/21/2026.
- Purchased $1,001 - $15,000 in shares of SailPoint NASDAQ: SAIL on 7/21/2026.
- Purchased $1,001 - $15,000 in shares of Glacier Bancorp NYSE: GBCI on 7/21/2026.
- Sold $1,001 - $15,000 in shares of FedEx NYSE: FDX on 7/21/2026.
Kenvue Stock Performance
Shares of Kenvue stock opened at $18.70 on Tuesday. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67. The business has a 50-day moving average price of $19.18 and a two-hundred day moving average price of $18.26. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $20.69. The company has a market cap of $35.92 billion, a P/E ratio of 21.49, a PEG ratio of 1.67 and a beta of 0.46.
Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.32 by ($0.01). Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The business had revenue of $3.96 billion during the quarter, compared to analyst estimates of $3.97 billion. During the same period in the prior year, the firm earned $0.29 earnings per share. The firm's revenue for the quarter was up 3.0% compared to the same quarter last year. As a group, analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.
Kenvue Increases Dividend
The company also recently declared a quarterly dividend, which was paid on Wednesday, August 26th. Shareholders of record on Wednesday, August 12th were given a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 4.5%. This is an increase from Kenvue's previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Wednesday, August 12th. Kenvue's payout ratio is currently 96.55%.
Hedge Funds Weigh In On Kenvue
A number of institutional investors have recently modified their holdings of KVUE. Elyxium Wealth LLC bought a new stake in Kenvue during the 4th quarter valued at $26,000. Johnson Financial Group Inc. acquired a new position in Kenvue during the second quarter worth $26,000. MV Capital Management Inc. bought a new position in shares of Kenvue in the fourth quarter valued at $28,000. CoreCap Advisors LLC lifted its stake in shares of Kenvue by 64.9% in the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company's stock valued at $29,000 after buying an additional 591 shares in the last quarter. Finally, Reflection Asset Management acquired a new position in shares of Kenvue during the fourth quarter valued at about $32,000. 97.64% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several equities analysts have issued reports on the company. Barclays boosted their price target on Kenvue from $18.00 to $19.00 and gave the company an "equal weight" rating in a research note on Tuesday, July 21st. Zacks Research lowered shares of Kenvue from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 7th. Wall Street Zen downgraded shares of Kenvue from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Weiss Ratings raised shares of Kenvue from a "hold (c-)" rating to a "hold (c)" rating in a research note on Monday, June 15th. Finally, UBS Group reduced their price target on shares of Kenvue from $20.00 to $19.00 and set a "neutral" rating for the company in a report on Tuesday, August 11th. Three analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $19.27.
Check Out Our Latest Stock Report on KVUE
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
Kenvue Company Profile
(
Get Free Report)
Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.